



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry Letters

journal homepage: www.elsevier.com/locate/bmcl



Tethered indoles as functionalizable ligands for the estrogen receptor

Bridget G. Trogden[†], Sung Hoon Kim, Shuyi Lee, John A. Katzenellenbogen^{*}

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA

ARTICLE INFO

Article history:

Received 18 September 2008

Revised 10 November 2008

Accepted 12 November 2008

Available online 18 November 2008

Keywords:

Estrogen receptor

Indole

PAMAM dendrimer

ABSTRACT

To create ligands for the estrogen receptor that contain pendant groups for tethering to a poly(amido)-amine (PAMAM) dendrimer, we have explored a class of *N*-substituted 2-phenyl indoles. Attachment of tethers of different length and chemical nature to this non-steroidal indole scaffold gave high affinity ligand-tether conjugates that can be easily functionalized. To further explore the utility of this system, an indole-conjugated dendrimer was prepared and evaluated as an estrogen receptor ligand.

© 2008 Elsevier Ltd. All rights reserved.

The estrogen receptor (ER) is a member of the nuclear hormone receptor superfamily of ligand-regulated transcription factors. The ER is regulated primarily by the endogenous estrogen, estradiol (E2, Fig. 1), but it is also the target of pharmaceutical agents, including estrogen agonists, antagonists, and selective estrogen receptor modulators (SERMs) that activate the subtypes ER α and ER β .¹ The binding of E2 or other agonists to ER results in conformational changes that affect its ability to recruit coactivators or corepressors and controls ER interaction with DNA-regulatory sequences, termed estrogen response elements.²

In addition to its nuclear role to regulate gene transcription, ER can also have non-genomic actions by directly activating kinase cascades. These non-genomic effects are more rapid than the transcriptional ones and are mediated through ER from membrane or other extranuclear sites, where it acts as a classical activator of signal transduction.³ Extranuclear ER is most likely the same protein as nuclear ER, yet it represents only a few percent of total cellular ER, so rigorous characterization of membrane ER has been difficult.

Estrogens conjugated to poly(amido)amine (PAMAM) dendrimers have been used to study the non-genomic, extranuclear effects of the estrogen receptor.^{4,5} We have found that when an estrogen is conjugated to the highly charged, abiotic PAMAM macromolecule, this estrogen-dendrimer conjugate remains outside of the nucleus, allowing the ligand to activate signaling of only non-nuclear, non-genomic pathways.

PAMAMs are available in a number of generations that correspond to progressively increasing molecular weights and surface functionalities. PAMAMs contain multiple surface amine substitu-

ents onto which ligands can be covalently attached. Generation-6 PAMAM has a nominal molecular weight of 58 kDa, similar to bovine serum albumin, which has been used as an estradiol carrier⁶; the dendrimer also has nominally 256 surface primary amines. A distinct advantage of a PAMAM over a protein as a macromolecule for hormone conjugation is that the PAMAM can withstand organic solvents and extraction protocols needed to remove any remaining free ligand, which can confound biological experiments.^{4–6}

Production of ER ligand-macromolecule conjugates involves four design steps: (I) identifying a good ligand scaffold with a position for covalent attachment of the tether, (II) determining an optimal tether length and chemical nature, (III) locating an appropriate linker type for synthetic ease in attachment to the dendrimer, and (IV) attachment of the dendrimer.

Regarding the first design step, adding a tether to various positions on E2 generally reduces its affinity, although substitution at 7 α , 11 β , or 17 α is typically well tolerated.⁷ Estradiol-macromolecular conjugates attached through 7 α or 17 α that we prepared bind well to ER and were useful as biological probes.^{4,5} Although these *steroidal* estrogen conjugates were useful, many interesting *non-steroidal* ligands for ER are known. While originally of interest because of their ease of synthesis, non-steroidal ligands have




Figure 1. Estradiol (E2) and 2-phenylindole estrogens.

^{*} Corresponding author.

E-mail address: jkatzene@uiuc.edu (J.A. Katzenellenbogen).

[†] Present address: Department of Chemistry, Mercer University, 1400 Coleman Ave, Macon, GA 31207, USA.

noteworthy biological profiles and have provided ER subtype-selective ligands and supplied new therapeutic agents.^{2,8,9} Thus, we were intrigued at the possibility of building functional ER-non-steroidal ligand conjugates, particularly those with macromolecules.

To investigate the tolerance of ER to macromolecule conjugates of non-steroidal ligands, we chose a series of 2-phenylindole ligands (Fig. 1). Many members of this class have pharmacological activity,^{10–18} and attachment of alkyl groups to the indole nitrogen generally provided favorable ER binding.^{10,17} The 2-phenylindole estrogens have been tested as inhibitors of mammary tumor growth¹⁵ and have been successfully attached to pendant chemotherapy agents to target ER⁺ tumors.¹¹

Recent reports show that the second design step can often be best achieved with short tethers.^{4,5,19} Addition of long or moderate-length tethers to ER ligands can sometimes decrease their accessibility to the receptor. Particularly when the ligand is conjugated to a macromolecule, shorter, more rigid tethers result in better exposure of the ligand to the receptor, by projecting the ligand outward, away from the conjugated molecule.⁵ Thus, ligands with shorter tethers often have affinity similar to that of the analogous ligands without these tethers.⁷ Thus, we prepared a small group of *N*-substituted 3-methyl-2-phenylindoles with tethers of various lengths and determined their binding affinities.


Using the Fischer indole synthesis (Scheme 1), 4-methoxyphenylhydrazine hydrochloride was reacted with 4-methoxypropionone to obtain dimethoxy protected 3-methyl-2-phenylindole **1**.

Deprotection of **1** with BBr₃ gave a dihydroxy indole intermediate, which was reprotected as the di-isopropyl ether **2**. This was necessary to avoid incompatibility during eventual removal of protecting groups from the indole and substituents placed on the indole nitrogen.

The protected indoles **1** and **2** were used to prepare tether-containing indoles to determine which attachment gives the highest affinity ER ligand (Table 1). Indoles **1** or **2** were treated with NaH followed by the appropriate electrophile to introduce *N*-benzyl or *N*-alkyl groups. The isopropyl groups were selectively cleaved with AlCl₃ to give products **3–4** and **6–7**, whereas treatment of the trimethoxy indoles with BBr₃ gave **5** and **8**.


The affinity of these modified indoles for ERα and ERβ was measured using a radiometric binding assay with [³H]estradiol as tracer.²⁰ The binding is expressed as relative binding affinity (RBA) values, which represent a percent of the binding affinity of the standard, E2 = 100% (Table 1). The affinities of these compounds are quite promising. Especially noteworthy are *N*-alkyl indole **7** and *N*-benzyl indole **4**, with ERα RBAs of 41% and 27%, respectively. These two compounds show that the ER is able to tolerate flexible tethers of some length on the N-1 position; thus, such compounds are viable candidates for further study. The ERα binding affinity of the other *N*-substituted indoles is also high, but in all cases, their ERβ affinity is less.

Some indoles were assayed for their agonistic and antagonistic character as regulators of transcription by co-transfection reporter



Scheme 1. Reagents and conditions: (a) HCl, EtOH, 80 °C, 6 h, 84%; (b) BBr₃, CH₂Cl₂, –78 °C to rt, 18 h, 82%; (c) 2-bromopropane, TBAH, acetone, 60 °C, 24 h, 46%.

Table 1
Synthesis and evaluation of estrogen receptor ligands




Reagents and conditions (a) NaH, electrophile, THF, 0 °C to r.t., 16–44%; (b) AlCl₃, CH₂Cl₂, r.t., 25–33%; (c) BBr₃, CH₂Cl₂, 0 °C to r.t., quant.


Compound	SM/deprotection scheme	R ²	ERα, ERβ relative binding affinity (RBA) ^a
3	2/(b)		11, 6.5
4	2/(b)		27, 1.2
5	1/(c)		10, 1.0
6	2/(b)		11, 2.0
7	2/(b)		41, 3.0
8	1/(c)		13, 1.4

^a Binding affinities are expressed as relative binding affinity (RBA) values, where the affinity of the tracer and native ligand estradiol is set at 100. The K_d of estradiol is 0.2 nM for ERα and 0.5 nM for ERβ.


For the fourth and final design step, we created an indole compound **18** having an aldehyde-substituted phenyl ring through which it could be conjugated to a PAMAM dendrimer (Scheme 3). Compound **18** was to be reacted with *N*-acetyl ethylenediamine to afford conjugate **19**, a reference compound whose structure

Compound	Structure	ER α , ER β relative binding affinity (RBA)
10	See Scheme 2	0.188, 0.084
11	See Scheme 2	2.17, 0.24
13	See Scheme 2	0.314, 0.046
15	See Scheme 2	0.226, 0.048
19		0.5 $\pm$ 0.1, 0.1 $\pm$ 0.1
20	See Scheme 3	1.3 $\pm$ 0.2 ^a , <0.007 ^a

Protecting group cleavage of **18** followed by reductive amination was also performed with the G-6 PAMAM dendrimer to pro-



Scheme 2. Reagents and conditions: (a) NaH, 4-(3-iodopropoxy)benzaldehyde, DMF, 79%; (b) EtSH, AlCl₃, rt, 89%-quant; (c) i-NH₂(CH₂)₂NHAc, MeOH, 65 °C; ii-NaBH₄, MeOH; (d) NaH, 4-iodobutylphthalimide, rt, 62–83%; (e) H₂NNH₂, CH₂Cl₂/CHCl₃, MeOH, rt, quant; (f) i-**16**, CH₂Cl₂, quant; ii-Pd/C, MeOH, quant.



Scheme 3. Reagents and conditions: (a) NaH, 4-iodobutylphthalimide, DMF, 0 °C to rt, 83%; (b) EtSH, AlCl₃, rt, 85%; (c) TBDMSCl, imidazole, DMF, 91%; (d) H₂NNH₂, CH₂Cl₂, MeOH, rt, 80%; (e) **21**, CH₂Cl₂, THF, rt, 80%; (f) H⁺, acetone, rt, 72%; (g) i-NH₂CH₂CH₂NHAc, CH₂Cl₂, ii-NaBH₄; (h) 1N HCl/MeOH, rt, quant; (i) i-G-6 PAMAM, MeOH, rt; ii-NaBH₄, quant.

vide the indole-PAMAM conjugate **20**, after removal of unreacted indole by membrane filtration, as we have previously described.⁴ Because the reductive amination reaction is highly efficient, the degree of dendrimer substitution by the indole ligand directly reflects the indole-to-PAMAM stoichiometric ratio.^{4,5} The uniformity of substitution was determined by MALDI MS, which showed an average of 25 indole substituents per PAMAM molecule, leaving approximately 230 free amines.²¹

The binding affinity analyses of **19** and **20** are given in Table 2. As an ER ligand, the reference compound **19** had relatively low affinity for both ER α and ER β . By contrast, the indole-PAMAM conjugate **20** showed respectable binding to ER α , with very high affinity preference (ca. 200-fold) for ER α over ER β . Notably, this is the first ligand-dendrimer conjugate that shows such a large ER α -selectivity, a finding that supports further study within this compound class.

In summary, we have prepared a series of *N*-substituted indoles having good binding affinities for the estrogen receptor and show the high tolerance of the ER for tethers of various lengths on N-1 of the 2-phenylindole. A dendrimer-conjugated indole was produced that had good affinity and selectivity for ER α . This novel compound can be used in further studies to characterize the biological functions of extranuclear ER.

Acknowledgments

This research was supported by a Grant from the NIH (PHS 5R37 DK15556). We thank Drs. F. Stossi and B. Katzenellenbogen for performing co-transfection assays and Kathryn Carlson for the binding assays.

References and notes

- Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *Science* **2002**, 295, 2380.
- Lin, X.; Huebner, V. *Curr. Opin. Drug Discov. Dev.* **2000**, 3, 383.
- Levin, E. R. *Steroids* **2002**, 67, 471.
- Kim, S. H.; Katzenellenbogen, J. A. *Angew. Chem. Int. Ed.* **2006**, 45, 7243.
- Harrington, W. R.; Kim, S. H.; Funk, C. C.; Madak-Erdogan, Z.; Schiff, R.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S. *Mol. Endocrinol.* **2006**, 20, 491.
- Stavis, P. E.; Deecher, D. C.; Suhadolnik, L.; Mallis, L. M.; Frail, D. E. *Endocrinology* **1999**, 140, 5455.
- Anstead, G. M.; Carlson, K. E.; Katzenellenbogen, J. A. *Steroids* **1997**, 62, 268.
- Veeneman, G. H. *Curr. Med. Chem.* **2005**, 12, 1077.
- Buijsman, R. C.; Hermkens, P. H.; van Rijn, R. D.; Stock, H. T.; Teerhuis, N. M. *Curr. Med. Chem.* **2005**, 12, 1017.
- von Angerer, E.; Prekajac, J.; Strohmeier, J. *J. Med. Chem.* **1984**, 27, 1439.
- Rink, S. M.; Yarema, K. J.; Solomon, M. S.; Paige, L. A.; Tadayoni-Rebek, B. M.; Essigmann, J. M.; Croy, R. G. *Proc. Natl. Acad. Sci. USA* **1996**, 93, 15063.
- Greenberger, L. M.; Annable, T.; Collins, K. L.; Komm, B. S.; Lyttle, C. R.; Miller, C. P.; Satyaswaroop, P. G.; Zhang, Y.; Frost, P. *Clin. Cancer Res.* **2001**, 7, 3166.
- Miller, C. P.; Collini, M. D.; Tran, B. D.; Harris, H. A.; Kharode, Y. P.; Marzolf, J. T.; Moran, R. A.; Henderson, R. A.; Bender, R. H. W.; Unwalla, R. J.; Greenberger, L. M.; Yardley, J. P.; Abou-Gharbia, M. A.; Lyttle, C. R.; Komm, B. S. *J. Med. Chem.* **2001**, 44, 1654.
- Biberger, C.; von Angerer, E. *J. Steroid Biochem. Mol. Bio.* **1998**, 64, 277.
- Biberger, C.; von Angerer, E. *J. Steroid Biochem. Mol. Bio.* **1996**, 58, 31.
- Golob, T.; Biberger, C.; Walter, G.; von Angerer, E. *Arch. Pharm.* **2000**, 333, 305.
- von Angerer, E.; Strohmeier, J. *J. Med. Chem.* **1987**, 30, 131.
- von Angerer, E.; Knebel, N.; Kager, M.; Ganss, B. *J. Med. Chem.* **1990**, 33, 2635.
- Ahmed, N.; Dubuc, C.; Rousseau, J.; Benard, F.; van Lier, J. E. *Bioorg. Med. Chem. Lett.* **2007**, 17, 3212.
- Carlson, K. E.; Choi, I.; Gee, A.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *Biochemistry* **1997**, 36, 14897.
- MALDI-TOF (DHB) Mn 57117, Mw 58260, PI 1.02 (reference G6 PAMAM dendrimer, Mn 46825, Mw 47573, PI 1.02: theoretical MW 58047). ¹H NMR (500 MHz, D₂O) 1.65 (indole, CH₂), 2.26 (G6), 2.42 (G6), 2.62 (G6), 2.85 (G6), 3.10 (G6), 3.23 (G6), 6.40–7.40 (m, indole).